中文

Increase the probability of your
products' success
dMed + Clinipace
Together as One

News & Events

APEIRON’s respiratory drug product to start pilot clinical trial to treat coronavirus disease COVID-1...2020-05-28

APEIRON Biologics AG, a biotechnology company with an approved product on the market as well as a broad preclinical and clinical pipeline, today announced the launch of a Pilot investigator-initiated c...

Read More

dMed and GenScript signed strategic agreement2020-04-20

dMed Biopharmaceutical (Shanghai) Co., Ltd., a global CRO based in China, and GenScript ProBio, CDMO business segment of GenScript Biotech Corporation, jointly announce that the parties will integrate ...

Read More

dMed raises nearly US$50 million in Series B financing to strengthen and expand its clinical operatio...2019-10-17

Shanghai, October 16, 2019 ---- dMed Biopharmaceutical Co., Ltd. recently announced completion of a nearly US$50 million Series B financing, led by Vivo Capital and joined by Legend Capital, Qiming Ven...

Read More

Target Health and dMed Biopharmaceuticals Join Forces to Help Western and Chinese Biopharma and Devic...2019-06-26

SHANGHAI and NEW YORK, June 24, 2019 /PRNewswire/ -- Target Health Inc. and dMed Biopharmaceuticals Company Limited have joined forces to help Western and Chinese biopharma and device companies capital...

Read More

dMed Biopharmaceutical announced the opening of its US Regulatory Affairs office in Washington DC2019-06-24

WASHINGTON, June 19, 2019 /PRNewswire/ -- Since the China launch earlier this year of an immuno-oncology drug at one-third the price of Merck's Keytruda, there has been a wave of applications for affor...

Read More

HOW CHINA IS CHANGING THE CLINICAL DEVELOPMENT LANDSCAPE2019-06-24

In less than 24 months, China has radically altered the global clinical development landscape, creating new pathways to commercialization that alter the traditional drug development paradigm.

Read More

dMed Forum in BioBay2019-03-28

dMed Forum was held successfully on March 20th in Suzhou BioBay, co-sponsored by dMed Biopharmaceutical Co., Ltd. & Suzhou Industry Park Pharmaceutical Association (SIPPA: http://www.sippa.org.cn/ ).

Read More

Lingshi Tan – Founder, Chairman and CEO, dMed, China2019-03-18

Dr Lingshi Tan, chairman and CEO of dMed, shares his strategic insights into the new era of Chinese biotech innovation and how it motivated him to leave Pfizer to establish dMed……

Read More

China:
298 Xiangke Road, 3/F, 301-305, Pudong New District, Shanghai 201210
Tel: +86 21 5090 0085 Fax: +86 21 6875 5515

United States:
3800 Paramount Pkwy, Suite 100 Morrisville, NC 27560
Tel: +1 919-224-8800

沪ICP备16041651号 Copyright © 2016-2021 dMed All Rights Reserved
沪公网安备 31011502005403号